The World Health Organization has indicated that it will be approximately 18 months before a vaccine for COVID-19 is developed. Using our approach will be more effective in vaccine development and will take half the amount of time it would take WHO to develop a vaccine.
We propose to harness information encoded by the immune system during active infection to generate therapeutic antibodies and develop vaccines (see model). Our approach is to capture information on immune responses from the active viral infection, amplify this response to develop cells that actively responded to infection. This information is then utilized to produce neutralizing antibodies for treating infected patients. Antibodies produced by B cells generated by our process are utilized to identify antigens using nano/LC/MS/MS for use in vaccine development. Our approach develops a database of all viral antigens to which infected patients body responded. Information gathered will also be useful to assess the efficacy of RNA based vaccines (Moderna and CureVac). Delivery for RNA vaccines is still challenging, and stability remains an issue. Our approach is far superior than any existing vaccine development technology and does not rely on injecting whole heat killed or attenuated pathogen. These old technologies are not only inferior, but they provide only partial protection and may show adverse events. We provide an opportunity to develop a tool kit to quickly respond to viral threats rapidly and cost effectively.